Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details specific share acquisitions by company leadership on December 9, 2014.
Management Commentary and Unusual Items
The filing discloses that nine Directors and PDMRs acquired GSK Ordinary Shares through the company's ShareReward Plan. The transactions occurred on December 9, 2014, at a price of 1,440.55 pence per share. The acquisitions included both personal contribution elements and matching elements (GSK contribution).
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, and Ms E Walmsley.
- Transaction Volume: Most participants acquired 9 shares under the personal contribution element and 9 shares under the matching element. Mr P C Thomson acquired 8 shares under each element.
Investor Verification Checklist
- Verify the total number of shares acquired by each Director and PDMR listed in the ShareReward Plan.
- Confirm the share price of 1,440.55 pence per Ordinary Share on December 9, 2014.
- Review the full terms of the GSK ShareReward Plan to understand the matching contribution structure.
- Check subsequent filings for any changes in director shareholdings or plan participation.